Sharescart Research Club logo

Krishna Inst.Medi Overview

1. Business Overview

Krishna Institute of Medical Sciences Ltd (KIMS) is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana, with a growing presence in Karnataka and Maharashtra. The company operates a chain of multi-specialty hospitals offering comprehensive tertiary and quaternary healthcare services. KIMS provides a wide range of medical services across specialties like cardiac sciences, oncology, neurosciences, gastric sciences, orthopedics, renal sciences, organ transplantation, and mother & child care. Its core business model revolves around providing inpatient and outpatient medical treatment, surgical procedures, diagnostics, and pharmacy services, generating revenue directly from patients, insurance companies, and government schemes.

2. Key Segments / Revenue Mix

KIMS primarily operates within the 'Hospital & Healthcare Services' industry. Its revenue is predominantly derived from its multi-specialty hospital operations. The major components of its revenue mix include:

Medical Services: Inpatient and outpatient consultations, treatments, surgeries, and procedures across various specialties.

Diagnostics: Laboratory tests, imaging services (MRI, CT scans, X-rays).

Pharmacy Sales: Revenue from in-hospital pharmacies.

While specific percentage breakdowns are not publicly available in detail, medical services constitute the bulk of its revenue.

3. Industry & Positioning

The Indian healthcare industry is characterized by significant growth, driven by an aging population, rising disposable incomes, increasing health awareness, growing prevalence of lifestyle diseases, and expanding health insurance penetration. The industry is fragmented, with both organized corporate chains and a large number of standalone hospitals and clinics. KIMS is positioned as a leading regional corporate healthcare provider, particularly strong in Andhra Pradesh and Telangana. It competes with other large national and regional hospital chains (e.g., Apollo, Fortis, Max Healthcare, Aster DM) as well as smaller local hospitals. KIMS focuses on providing quality multi-specialty care at relatively affordable price points, aiming for operational efficiency and patient volume.

4. Competitive Advantage (Moat)

Regional Scale & Brand Reputation: KIMS has established a strong brand name and significant market share in its core geographies of Andhra Pradesh and Telangana, building trust and recognition among patients and referring physicians.

Doctor Relationships: Long-standing relationships with a strong panel of experienced doctors and consultants are crucial in healthcare and contribute to patient loyalty.

Operational Efficiency: The company has demonstrated a focus on operational efficiency, which helps maintain competitive pricing and profitability.

Network Effect (within region): A growing network of hospitals within its primary operating regions allows for better patient referrals and resource optimization.

5. Growth Drivers

Increasing Demand for Healthcare: Driven by demographics (aging population, rising chronic diseases), urbanization, and growing health insurance coverage.

Expansion in Existing & New Geographies: Both brownfield (capacity expansion in existing hospitals) and greenfield (new hospital construction) expansion, along with strategic acquisitions, are key to growth. KIMS has been expanding beyond its core regions.

Medical Value Travel: India's growing appeal as a destination for medical tourism presents an opportunity for KIMS to attract international patients.

Focus on High-Value Specialties: Continued investment and strengthening of specialties like organ transplantation, oncology, and cardiac sciences that command higher revenue per patient.

Digital Health Integration: Leveraging technology for patient engagement, telemedicine, and operational efficiency.

6. Risks

Regulatory & Pricing Pressure: Government interventions like price caps on medical procedures (e.g., stents, knee implants) or Ayushman Bharat scheme tariffs can impact profitability. Changes in health insurance regulations also pose a risk.

Intense Competition: The healthcare sector is highly competitive, potentially leading to pricing pressure and challenges in attracting and retaining medical talent.

Doctor & Staff Attrition: Reliance on key medical professionals means a loss of critical doctors can impact patient volumes and reputation. Rising staff costs are also a concern.

High Capital Expenditure: Expanding the hospital network requires significant capital investment, leading to potential debt accumulation and execution risks.

Litigation & Medical Malpractice: The inherent risk of medical errors leading to legal challenges and reputational damage.

Economic Downturns: Can impact affordability for elective procedures and overall patient footfall.

7. Management & Ownership

KIMS is a promoter-led company. Dr. Bhaskar Rao, a renowned cardiothoracic surgeon, is the founder, Chairman, and Managing Director, playing a pivotal role in the company's growth and strategic direction. The management team generally comprises experienced professionals with a strong understanding of the healthcare delivery model in India. The ownership structure includes the promoter group holding a significant stake, along with institutional investors (domestic and foreign) and public shareholders. The promoter's strong medical background and long-standing experience in hospital management are key strengths.

8. Outlook

KIMS is well-positioned to capitalize on the robust growth in the Indian healthcare sector, driven by increasing demand and evolving patient needs. Its established brand equity and strong network in its core markets provide a solid foundation. The company's strategy of calibrated expansion into new geographies and focus on operational efficiency should support future growth. However, the outlook is balanced by inherent industry risks, including potential regulatory price controls, intense competition for talent and patients, and the high capital expenditure required for sustained growth. Successfully integrating new acquisitions and managing cost pressures will be crucial for maintaining its profitability and market position.

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Krishna Inst.Medi Key Financials

Market Cap ₹28684 Cr.

Stock P/E 69.2

P/B 12.8

Current Price ₹716.9

Book Value ₹ 56.2

Face Value 2

52W High ₹798

Dividend Yield 0%

52W Low ₹ 575.6

Krishna Inst.Medi Share Price

| |

Volume
Price

Krishna Inst.Medi Quarterly Price

Show Value Show %

Krishna Inst.Medi Peer Comparison

Krishna Inst.Medi Quarterly Results

#(Fig in Cr.) Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 606 634 688 777 772 797 872 961 998 1075
Other Income 3 4 5 5 18 5 7 4 5 10
Total Income 609 638 693 782 790 801 879 965 1003 1084
Total Expenditure 459 475 509 559 585 599 679 757 799 868
Operating Profit 150 163 184 223 205 203 200 208 204 216
Interest 12 16 18 20 26 27 33 45 57 68
Depreciation 35 46 39 41 45 53 53 66 79 85
Exceptional Income / Expenses 0 0 0 0 0 11 0 -0 0 -11
Profit Before Tax 103 100 127 162 135 134 114 97 69 52
Provision for Tax 26 29 32 42 42 28 29 25 17 22
Profit After Tax 77 72 95 121 93 106 85 72 52 31
Adjustments -5 -6 -9 -13 -4 -4 -6 -5 2 12
Profit After Adjustments 72 66 87 107 89 102 79 67 53 43
Adjusted Earnings Per Share 1.8 1.6 2.2 2.7 2.2 2.5 2 1.7 1.3 1.1

Krishna Inst.Medi Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 420 512 567 664 918 1123 1330 1651 2198 2498 3035 3906
Other Income 4 5 3 34 6 6 10 20 37 16 32 26
Total Income 424 516 570 698 924 1129 1340 1671 2235 2514 3067 3931
Total Expenditure 342 403 508 592 833 873 954 1129 1598 1854 2242 3103
Operating Profit 81 113 63 106 90 256 386 542 637 661 825 828
Interest 35 37 80 88 49 44 37 22 37 55 100 203
Depreciation 32 35 36 40 56 71 70 73 129 147 177 283
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 15 0 11 -11
Profit Before Tax 14 41 -53 -22 -15 141 279 457 485 460 558 332
Provision for Tax 7 13 18 26 34 25 74 113 119 124 143 93
Profit After Tax 7 28 -71 -48 -49 115 205 344 366 336 415 240
Adjustments -2 -1 -0 1 1 4 -4 -11 -29 -26 -30 3
Profit After Adjustments 6 27 -71 -47 -48 119 201 333 336 310 385 242
Adjusted Earnings Per Share 0.2 0.8 -2.8 -1.9 -1.3 3.2 5.2 8.3 8.4 7.8 9.6 6.1

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 21% 23% 22% 22%
Operating Profit CAGR 25% 15% 26% 26%
PAT CAGR 24% 6% 29% 50%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 11% 33% NA% NA%
ROE Average 21% 21% 25% 3%
ROCE Average 19% 22% 27% 18%

Krishna Inst.Medi Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 238 263 -113 -158 541 598 864 1387 1670 1828 2138
Minority's Interest 6 7 5 21 25 13 12 23 268 265 281
Borrowings 201 174 199 249 243 269 185 138 497 928 1654
Other Non-Current Liabilities 42 47 45 53 104 96 94 141 169 347 767
Total Current Liabilities 170 174 629 745 201 219 278 215 296 452 836
Total Liabilities 657 665 764 910 1114 1194 1433 1904 2901 3820 5676
Fixed Assets 511 515 523 711 863 916 931 1005 1766 2434 3349
Other Non-Current Assets 46 35 96 43 77 59 51 506 657 839 1630
Total Current Assets 101 115 146 156 174 220 451 393 478 547 697
Total Assets 657 665 764 910 1114 1194 1433 1904 2901 3820 5676

Krishna Inst.Medi Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 9 14 3 8 11 8 41 52 26 62 47
Cash Flow from Operating Activities 64 95 83 106 134 202 356 324 432 521 582
Cash Flow from Investing Activities -71 -41 -70 -64 -110 -125 -354 -412 -547 -753 -1116
Cash Flow from Financing Activities 12 -65 -8 -39 -27 -44 10 61 20 217 543
Net Cash Inflow / Outflow 5 -11 5 3 -3 32 12 -26 -95 -15 9
Closing Cash & Cash Equivalent 14 3 8 11 8 41 52 26 62 47 56

Krishna Inst.Medi Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.16 0.76 -2.84 -1.88 -1.28 3.2 5.19 8.31 8.41 7.75 9.61
CEPS(Rs) 1.12 1.8 -1.39 -0.32 0.2 4.99 7.09 10.41 12.37 12.06 14.8
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 6.77 7.48 -4.51 -6.31 14.51 16.05 22.26 34.67 41.72 45.71 53.45
Core EBITDA Margin(%) 18.41 21.27 10.49 10.76 9.22 22.22 28.25 31.6 27.27 25.81 26.13
EBIT Margin(%) 11.72 15.23 4.73 9.97 3.74 16.48 23.79 29 23.76 20.57 21.7
Pre Tax Margin(%) 3.37 7.99 -9.33 -3.31 -1.64 12.52 20.98 27.67 22.06 18.39 18.39
PAT Margin (%) 1.72 5.47 -12.48 -7.2 -5.29 10.25 15.45 20.83 16.65 13.45 13.67
Cash Profit Margin (%) 9.4 12.4 -6.14 -1.23 0.82 16.54 20.68 25.23 22.53 19.31 19.51
ROA(%) 1.11 4.23 -9.91 -5.71 -4.8 9.97 15.64 20.6 15.23 10 8.74
ROE(%) 3.31 11.15 -94.27 0 -25.44 20.22 28.12 30.55 23.93 19.21 20.92
ROCE(%) 9.91 14.96 5.18 12.42 4.99 21.17 30.82 35.69 27.84 20.25 19.04
Receivable days 29.46 37.01 47.56 51.94 45.88 41.54 33.22 26.36 31.66 39.96 41.48
Inventory Days 9.93 8.4 9.24 10.05 9.34 9.3 7.47 6.69 6.58 6.74 6.82
Payable days 199.08 186.41 192.4 196.7 172.78 163.35 161.26 134.33 115.35 127.64 135.6
PER(x) 0 0 0 0 0 0 0 33.2 33.46 53.11 66.51
Price/Book(x) 0 0 0 0 0 0 0 7.96 6.74 9.01 11.96
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.67 0.62 1.18 1.12 0.38 0.31 0.05 6.67 5.33 6.99 9.03
EV/Core EBITDA(x) 3.43 2.81 10.69 7.05 3.89 1.37 0.16 20.33 18.41 26.43 33.21
Net Sales Growth(%) 19.56 21.95 10.81 17.02 38.32 22.29 18.46 24.13 33.13 13.67 21.49
EBIT Growth(%) 4.4 58.49 -65.61 146.73 -48.04 438.28 71.03 51.33 9.08 -1.57 28.11
PAT Growth(%) 29.18 288.58 -353.08 32.49 -1.66 336.84 78.57 67.31 6.4 -8.18 23.49
EPS Growth(%) -6.46 374.56 -475.97 33.83 31.98 350.09 62.08 60.3 1.09 -7.79 24.03
Debt/Equity(x) 1.19 0.97 -5.56 -4.47 0.53 0.54 0.31 0.12 0.32 0.57 0.89
Current Ratio(x) 0.59 0.66 0.23 0.21 0.87 1 1.62 1.83 1.61 1.21 0.83
Quick Ratio(x) 0.53 0.59 0.21 0.18 0.73 0.87 1.53 1.66 1.47 1.1 0.76
Interest Cover(x) 1.4 2.1 0.34 0.75 0.7 4.16 8.47 21.89 14.01 9.43 6.56
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0.01 0.05 0.06 0.07

Krishna Inst.Medi Shareholding Pattern

# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 38.82 38.82 38.82 38.82 38.82 38.82 34.11 34.11 34.11 34.11
FII 15.27 16.73 17.84 15.85 15.68 15.45 15.54 15.03 14.33 14.57
DII 34.23 33.13 32.12 32.3 32.05 31.95 31.65 32.12 32.61 32.38
Public 11.68 11.32 11.22 13.03 13.45 13.78 18.69 18.75 18.95 18.94
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Krishna Inst.Medi News

Krishna Inst.Medi Pros & Cons

Pros

  • Company has delivered good profit growth of 29% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 21%

Cons

  • Promoter holding is low: 34.11%.
  • Debtor days have increased from 127.64 to 135.6days.
  • Stock is trading at 12.8 times its book value.
whatsapp